Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-topoisomerase II alpha (TOP2A) is a critical nuclear enzyme that manages DNA topology by creating transient double-strand breaks to allow the passage of one DNA duplex through another (Source: UniProt P11388). The cleavage complex is the specific intermediate state where the enzyme is covalently linked to the 5' ends of the broken DNA via a tyrosyl-phosphate bond (Source: Nitiss, J. L., Nat Rev Cancer, 2009). While this state is normally short-lived, it is the primary target for a class of chemotherapy drugs known as topoisomerase II poisons, such as etoposide and doxorubicin. These drugs stabilize the complex, preventing the religation of the DNA strands and effectively converting an essential enzyme into a cellular toxin (Source: Pommier, Y., Nat Rev Cancer, 2013). The resulting accumulation of permanent DNA double-strand breaks triggers apoptotic pathways, making it a potent strategy for treating rapidly dividing cancer cells. TOP2A is frequently overexpressed in various malignancies, correlating with high proliferation rates and serving as both a therapeutic target and a prognostic biomarker in oncology (Source: StatPearls, Topoisomerase Inhibitors).
Topoisomerase II poisons stabilize the transient covalent complex between the enzyme and DNA, preventing the religation of the DNA strands and leading to the formation of permanent double-strand breaks that trigger apoptosis (Source: Pommier, Y., Nat Rev Cancer, 2013).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-topoisomerase II alpha cleavage complex (TOP2A-DNA CC) (TOP2A-DNA CC).